Literature DB >> 35266925

Improvement of Mineral and Bone Disorders After Renal Transplantation.

Ana Carina Ferreira1,2, Marco Mendes1, Cecília Silva1, Patrícia Cotovio1, Inês Aires1,2, David Navarro1, Fernando Caeiro1, Rúben Ramos3, Rute Salvador4, Bruna Correia4, Guadalupe Cabral4, Fernando Nolasco1,2, Aníbal Ferreira1,2.   

Abstract

BACKGROUND: Posttransplant mineral and bone diseases are causes of fractures, and their association with cardiovascular events is being studied.
METHODS: We analyzed the evolution of biochemical, histological, and imaging parameters pre- and 1 y post-renal transplantation in 69 patients and correlated mineral and bone findings with coronary calcifications. At inclusion and after 12 mo, clinical data and echocardiographic findings were recorded, and laboratory evaluations, radiography of the pelvis and hands, and bone biopsy were performed. Noncontrast cardiac computed tomography was performed during the second evaluation.
RESULTS: Serum levels of fibroblast growth factor 23 and sclerostin decreased in all patients, parathyroid hormone levels decreased in 89.8% of patients, bone alkaline phosphatase levels decreased in 68.1% of patients, and alpha-Klotho levels increased in 65.2% of patients. More than half of the patients presented with renal osteodystrophy at both biopsies, but histological findings improved: a significant transition from high to normal or low turnover and no significant differences in volume, mineralization defect, or cortical porosity at the 2 evaluations. Alpha-Klotho, sclerostin, and bone alkaline phosphatase shifts affect bone changes. Neither echocardiographic findings nor vascular calcification scores differed between the 2 points. Both the pretransplant period (dialysis vintage, sclerostin, and low bone volume at baseline) and the maintenance of abnormalities in the posttransplant period (high turnover posttransplant) were the most reliable predictors of the severity of the coronary calcification percentile.
CONCLUSIONS: Renal transplantation improved bone and mineral abnormalities. The pretransplant period determines the severity of calcification.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35266925      PMCID: PMC9038238          DOI: 10.1097/TP.0000000000004099

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   5.385


  50 in total

Review 1.  Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.

Authors:  Wacharee Seeherunvong; Myles Wolf
Journal:  Pediatr Transplant       Date:  2010-10-08

2.  Sclerostin in CKD-MBD: one more paradoxical bone protein?

Authors:  Guillaume Jean; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2013-09-12       Impact factor: 5.992

3.  Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients.

Authors:  Pieter Evenepoel; Kathleen Claes; Bjorn Meijers; Michaël R Laurent; Bert Bammens; Maarten Naesens; Ben Sprangers; Hans Pottel; Etienne Cavalier; Dirk Kuypers
Journal:  Kidney Int       Date:  2019-03-04       Impact factor: 10.612

4.  Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.

Authors:  Hartmut H Malluche; Hanna W Mawad; Marie-Claude Monier-Faugere
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

5.  Changes in Bone Histomorphometry after Kidney Transplantation.

Authors:  Satu Keronen; Leena Martola; Patrik Finne; Inari S Burton; Heikki Kröger; Eero Honkanen
Journal:  Clin J Am Soc Nephrol       Date:  2019-05-14       Impact factor: 8.237

6.  High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study.

Authors:  Christiane Drechsler; Pieter Evenepoel; Marc G Vervloet; Christoph Wanner; Markus Ketteler; Nikolaus Marx; Jürgen Floege; Friedo W Dekker; Vincent M Brandenburg
Journal:  Nephrol Dial Transplant       Date:  2014-09-23       Impact factor: 5.992

Review 7.  Bone disease after renal transplantation.

Authors:  Hartmut H Malluche; Marie-Claude Monier-Faugere; Johann Herberth
Journal:  Nat Rev Nephrol       Date:  2009-11-17       Impact factor: 28.314

8.  The Role of Bone Volume, FGF23 and Sclerostin in Calcifications and Mortality; a Cohort Study in CKD Stage 5 Patients.

Authors:  Ana Carina Ferreira; Patrícia Cotovio; Inês Aires; Marco Mendes; David Navarro; Cecília Silva; Fernando Caeiro; Rute Salvador; Bruna Correia; Guadalupe Cabral; Fernando Nolasco; Aníbal Ferreira
Journal:  Calcif Tissue Int       Date:  2021-09-03       Impact factor: 4.333

9.  Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.

Authors:  Julia J Scialla; Wei Ling Lau; Muredach P Reilly; Tamara Isakova; Hsueh-Ying Yang; Matthew H Crouthamel; Nicholas W Chavkin; Mahboob Rahman; Patricia Wahl; Ansel P Amaral; Takayuki Hamano; Stephen R Master; Lisa Nessel; Boyang Chai; Dawei Xie; Radhakrishna R Kallem; Jing Chen; James P Lash; John W Kusek; Matthew J Budoff; Cecilia M Giachelli; Myles Wolf
Journal:  Kidney Int       Date:  2013-02-06       Impact factor: 10.612

10.  Fibroblast growth factor 23 expression in human calcified vascular tissues.

Authors:  Javier Donate-Correa; Ernesto Martín-Núñez; Carolina Hernández-Carballo; Carla Ferri; Víctor G Tagua; Alejandro Delgado-Molinos; Ángel López-Castillo; Sergio Rodríguez-Ramos; Purificación Cerro-López; Victoria Castro López-Tarruella; Raquel Felipe-García; Miguel A Arévalo-Gomez; Nayra Pérez-Delgado; Carmen Mora-Fernández; Juan F Navarro-González
Journal:  Aging (Albany NY)       Date:  2019-09-22       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.